logo
logo
HAE stock ticker logo

Haemonetics Corporation

NYSE•HAE
CEO: Mr. Christopher A. Simon
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 1991-05-10
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
連絡先情報
125 Summer Street, Boston, MA, 02110, United States
781-848-7100
www.haemonetics.com
時価総額
$2.78B
PER (TTM)
15.9
36
配当利回り
--
52週高値
$87.32
52週安値
$47.32
52週レンジ
30%
順位21Top 7.6%
6.0
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2026 データ

売上高

$338.97M+0.00%
直近4四半期の推移

EPS

$0.96+0.00%
直近4四半期の推移

フリーCF

$87.22M+0.00%
直近4四半期の推移

2026 Q3 決算ハイライト

主なハイライト

Operating Income Strong Growth Operating Income reached $179.8M for nine months, showing strong 19.5% reported growth driven by pricing and lower restructuring.
Net Income Improvement Net Income grew 7.1% to $117.5M for nine months, benefiting from margin expansion and cost control efforts.
Gross Margin Expansion Gross Margin expanded to 59.7% (9M), a 5.7 point increase driven by continued product portfolio transformation efforts.
Operating Cash Flow Surge Operating Cash Flow surged to $222.3M (9M), significantly higher than $65.2M provided in the prior year nine months period.

リスク要因

Top Line Revenue Decline Net Revenues declined 4.1% to $987.7M (9M), impacted by Whole Blood divestiture and major customer transition.
Intangible Asset Impairment Intangible asset impairment charge reached $9.3M (9M), a 289.0% increase year-over-year related to HemoAssay IP.
Near-Term Debt Maturity Significant debt maturity risk as $300.0M principal balance of 2026 Notes is scheduled to mature March 1, 2026.
Foreign Exchange Volatility High foreign exchange exposure exists; international sales comprised 26.1% of total revenue for the nine months ended period.

見通し

Vivasure Medical Acquisition Acquired Vivasure Medical for $116.4M upfront cash, expanding Hospital unit portfolio in interventional cardiology market.
Share Repurchase Program Active New $500.0M share repurchase program approved through April 2028; $425.0M remains authorized as of December 27.
Restructuring Costs Decreasing Restructuring costs significantly decreased to $3.1M (3M period) as prior portfolio rationalization initiatives are now closed.
Revenue Backlog Visibility $36.6M of remaining performance obligations expected to be recognized as revenue within the next twelve months.

同業比較

売上高 (TTM)

BHC stock ticker logoBHC
$10.31B
+7.1%
XRAY stock ticker logoXRAY
$3.68B
-3.0%
ACHC stock ticker logoACHC
$3.31B
+5.0%

粗利益率 (最新四半期)

AGIO stock ticker logoAGIO
96.9%
-4.3pp
BEAM stock ticker logoBEAM
95.0%
-471.3pp
CPRX stock ticker logoCPRX
90.8%
-2.1pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
ITGR$2.92B28.26.0%41.0%
WRBY$2.88B1764.90.5%32.3%
CPRX$2.87B13.324.3%0.3%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
0.8%
緩やかな成長
4四半期純利益CAGR
-8.3%
収益性の低下
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年5月6日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし